BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: Implications for melanoma staging and adjuvant therapy
European Journal of Cancer2014Vol. 50(15), pp. 2668–2676
Citations Over TimeTop 12% of 2014 papers
Andrew P. Barbour, Yue Tang, Nicola Armour, Ken Dutton‐Regester, Lutz Krause, Kelly A. Loffler, Duncan Lambie, Bryan Burmeister, Janine Thomas, B. Mark Smithers, Nicholas K. Hayward
Related Papers
- → Relationship of cell-mediated cytotoxicity against melanoma cells to prognosis in melanoma patients(1978)41 cited
- → Inhibition of leukocyte migration in agarose by KC1 extracts of a human melanoma cell line grown in serum‐free medium(1975)16 cited
- Immune Adjuvant Effect of CFNCpG Motif on Antigen of Inactivated BVDV1(2008)
- Research progress of aluminum adjuvant(2015)
- → ADJUVANTS(1994)